Results 221 to 230 of about 177,679 (314)

New variants of fuzzy optimal control problems

open access: yesAsian Journal of Control, EarlyView.
Abstract This study introduces a groundbreaking approach to optimal control problems by incorporating fuzzy conformable derivatives. Our primary goal is to identify the optimal control strategy that maximizes fuzzy performance indices while adhering to fuzzy conformable dynamical systems.
Awais Younus   +3 more
wiley   +1 more source

Sustainable biofuel production from fish processing waste: lipase‐catalyzed hydroesterification of tilapia residual oil

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Fishing waste and byproducts, whether naturally occurring or from industrial processing, are important sources of high‐value compounds. Fertilizers, biomaterials, cosmetics, biolubricants, and biodiesel are some of the substances that can be obtained from these residues. The objective of this study was to conduct a theoretical and experimental
Patrick da Silva Sousa   +7 more
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi   +11 more
wiley   +1 more source

Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Derek Z. Yang   +9 more
wiley   +1 more source

Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Junjie Ding   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy